XML 46 R40.htm IDEA: XBRL DOCUMENT
v2.4.0.6

License and Collaboration Agreements (Narrative) (Detail) (USD $) | 12 Months Ended | 1 Months Ended | 6 Months Ended | 12 Months Ended |  | 12 Months Ended |  | 3 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended |  | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 30, 2012 Year | Jun. 30, 2011 | Jun. 30, 2010 | Jun. 30, 2012 Alimera | Dec. 31, 2009 Alimera Month | Jun. 30, 2012 Alimera | Jun. 30, 2011 Alimera | Jun. 30, 2010 Alimera | Jan. 31, 2008 Alimera | Jun. 30, 2012 Pfizer Collaboration Agreement | Jun. 30, 2011 Pfizer Collaboration Agreement | Jun. 30, 2008 Pfizer Collaboration Agreement | Jun. 30, 2011 Pfizer Collaboration Agreement Restated | Jun. 30, 2011 Pfizer Collaboration Agreement Restated | Jul. 31, 2011 Intrinsiq Materials Cayman Limited | Jul. 31, 2009 Intrinsiq Materials Cayman Limited | Sep. 30, 2011 Intrinsiq Materials Cayman Limited | Jun. 30, 2011 Intrinsiq Materials Cayman Limited | Jun. 30, 2010 Intrinsiq Materials Cayman Limited | Jan. 31, 2008 Intrinsiq Materials Cayman Limited | Jun. 30, 2012 Bausch and Lomb | Jun. 30, 2011 Bausch and Lomb | Jun. 30, 2010 Bausch and Lomb
Collaborative Agreements And Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration received in cash |  |  |  | $ 12,000,000 |  | $ 12,000,000 |  |  | $ 1,200,000.0 |  |  |  | $ 10,050,000 | $ 10,050,000 |  |  |  |  |  |  |  |  |
Accrued development cost liabilities |  |  |  | 5,700,000 |  | 5,700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Conditional note received |  |  |  | 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment upon FDA approval | 25,000,000 |  |  | 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share in future profits |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of decrease in share of future profits |  |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pre-profitability net losses percentage |  |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalties |  |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of non-royalty consideration received |  |  |  |  |  | 33.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | 18,300,000 |  |  |  |  |  |  |  | 7,750,000 | 7,750,000 |  |  |  |  |  |  |  |  |
Period of revenue recognized from the effective date of agreement |  |  |  |  | 21.5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue related to agreement |  |  |  |  |  | 111,000.0 | 192,000.0 | 22,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research Funding |  |  |  |  |  |  |  |  |  |  | 500,000 | 500,000 |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  |  |  | 2,300,000 |  |  | 2,300,000 |  |  |  |  |  |  |  |  |
License option right |  |  |  |  |  |  |  |  |  |  | 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Development and sales performance milestone maximum |  |  |  |  |  |  |  |  |  |  | 146,500,000 |  |  |  |  |  |  |  |  |  |  |  |
Collaborative research and development revenue |  | 3,300,000 |  |  |  |  |  |  |  | 754,000.0 | 3.3 |  | 3,300,000 |  |  |  | 1,100,000 | 83,000 | 121,000 |  |  |  |
Collaborative research and development revenue |  |  |  |  |  |  |  |  |  |  | 6,700,000 |  |  |  |  |  |  |  |  |  |  |  |
Collaborative research and development revenue over the expected performance period |  |  |  |  |  |  |  |  |  |  | 3 years 6 months |  |  |  |  |  |  |  |  |  |  |  |
Obligated aggregate minimum royalties to be paid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,550,000 |  |  |
Royalties | 1,446,000 | 1,353,000 | 483,000 |  |  |  |  |  |  |  |  |  |  |  |  | 450,000 |  |  |  |  | 1,446,000 | 1,353,000 | 483,000
Period of revenue recognized from the effective date of agreement | 17 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capital equipment assets | 405,000 | 133,000 | 15,000 |  |  |  |  |  |  |  |  |  |  |  | 223,000 |  |  |  |  |  |  |  |
Additional royalty income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,200,000
Accounts receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 442,000 | $ 290,000 |

X
- Definition Accounts Receivable Current + References No definition available. + Details
Name: | psdv_AccountsReceivableCurrent
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Accrued Development Cost Liabilities Cancelled + References No definition available. + Details
Name: | psdv_AccruedDevelopmentCostLiabilitiesCancelled
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreement Cash Consideration Received + References No definition available. + Details
Name: | psdv_CollaborationAgreementCashConsiderationReceived
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Revenue + References No definition available. + Details
Name: | psdv_CollaborationRevenue
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | psdv_CollaborativeAgreementsAndContractsLineItems
Namespace Prefix: | psdv_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Conditional Note Received + References No definition available. + Details
Name: | psdv_ConditionalNoteReceived
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Future Minimum Royalty Commitments Total + References No definition available. + Details
Name: | psdv_FutureMinimumRoyaltyCommitmentsTotal
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License Option Right + References No definition available. + Details
Name: | psdv_LicenseOptionRight
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Measurement Performance Period + References No definition available. + Details
Name: | psdv_MeasurementPerformancePeriod
Namespace Prefix: | psdv_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone Payment Due Upon Approval By Fda + References No definition available. + Details
Name: | psdv_MilestonePaymentDueUponApprovalByFda
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone Payments Maximum Amount + References No definition available. + Details
Name: | psdv_MilestonePaymentsMaximumAmount
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum Amount of Consideration Received from Research Program + References No definition available. + Details
Name: | psdv_MinimumAmountOfConsiderationReceivedFromResearchProgram
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Non Royalty Consideration Percentage + References No definition available. + Details
Name: | psdv_NonRoyaltyConsiderationPercentage
Namespace Prefix: | psdv_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period Of Identified Performane Obligations Under Licence Agreement Recognized As Research And Development Revenue + References No definition available. + Details
Name: | psdv_PeriodOfIdentifiedPerformaneObligationsUnderLicenceAgreementRecognizedAsResearchAndDevelopmentRevenue
Namespace Prefix: | psdv_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period Of Unamortized Milestone Payments, Recognized As Revenue + References No definition available. + Details
Name: | psdv_PeriodOfUnamortizedMilestonePaymentsRecognizedAsRevenue
Namespace Prefix: | psdv_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Profit Sharing On Sale Of Product Percentage + References No definition available. + Details
Name: | psdv_ProfitSharingOnSaleOfProductPercentage
Namespace Prefix: | psdv_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Profit Sharing Percent Under Former Collaboration + References No definition available. + Details
Name: | psdv_ProfitSharingPercentUnderFormerCollaboration
Namespace Prefix: | psdv_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research Revenue Recognized In Collaboration + References No definition available. + Details
Name: | psdv_ResearchRevenueRecognizedInCollaboration
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty Rate Percentage + References No definition available. + Details
Name: | psdv_RoyaltyRatePercentage
Namespace Prefix: | psdv_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Revenue Offset + References No definition available. + Details
Name: | psdv_RoyaltyRevenueOffset
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Share Percentage Of Pre-profitability Net Losses On Sale Of Product + References No definition available. + Details
Name: | psdv_SharePercentageOfPreprofitabilityNetLossesOnSaleOfProduct
Namespace Prefix: | psdv_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront Cash Payment + References No definition available. + Details
Name: | psdv_UpfrontCashPayment
Namespace Prefix: | psdv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. + Details
Name: | us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 25 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771336&loc=SL6750900-111635 + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration